Schizophrenia News

An oral, ultra-long-acting, extended-release risperidone capsule provided sustained therapeutic levels of risperidone over 1-week dosing intervals, according to results of a randomized, parallel group, placebo-controlled study.

The FDA has approved an olanzapine/samidorphan combination treatment for schizophrenia and bipolar 1 disorder in adults.

A new digital intervention added to treatment as usual improved vocational or educational attainment and reduced usage of hospital emergency services in first-episode psychosis, according to results of a randomized controlled trial.

Researchers conducted an umbrella review of interventions for mental disorders among youths that provided evidence-based information for clinical decision making.

Researchers have developed an algorithm tailored to age that can predict the risk for incident metabolic syndrome among young people with psychosis, according to study results published in The Lancet Psychiatry.

Anticholinergic medication burden is substantial among individuals with schizophrenia, according to results of a cross-sectional data analysis published in American Journal of Psychiatry.

Medicare patients with schizophrenia had increased risk for suicide, with young adults having the highest absolute and relative risk, according to study results published in JAMA Psychiatry.

Psychiatric conditions were associated with a younger age at onset of Alzheimer’s disease, and age differences only grew with each additional psychiatric diagnosis, researchers reported.

A video-based intervention for young adults appeared effective at humanizing schizophrenia and reducing stigma surrounding the diagnosis, according to results of a randomized controlled trial published in American Journal of Psychiatry.

Physicians should monitor cardiometabolic markers among patients on antipsychotics, according to results of a retrospective study presented at the American Psychiatric Association’s annual meeting.